Texcell, a contract research organization (CRO) that specializes in viral testing, viral clearance, bioassays, in vivo testing, and GMP cell banking, has opened its newest testing facility in Frederick, MD. 

In a statement, the company said that the new building represents a significant milestone in Texcell’s commitment to advancing the viral safety of biotherapeutics and medical devices.

Designed to support simultaneous viral clearance and biosafety studies, this 27,000 square-foot facility is built with a modular design that enhances the flexibility required in today’s contract testing environment.

The new facility will support biosafety studies for monoclonal antibodies, gene therapies, and medical devices coming to the market.